2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.077 Marie Dreyer NACLC23 Abstract

PP01.077 Marie Dreyer NACLC23 Abstract

Pdf Summary

Biomarker testing plays a crucial role in the treatment of non-small cell lung cancer (NSCLC), but widespread utilization of this testing has been limited by various challenges. In this study, researchers interviewed clinicians involved in the care of NSCLC patients to identify current practices and challenges associated with conducting biomarker testing in their health system. The study took place between January and May 2022 in a large academic medical center.<br /><br />The researchers found that the processes for ordering and receiving biomarker testing varied depending on whether the tests were conducted internally or externally. They identified several barriers to biomarker testing, including general cost concerns, Medicare rules disallowing billing for testing during hospitalization, and lack of a standardized pre-authorization process. Variability in ordering tests and receiving results was another challenge faced by clinicians. Internal testing also faced competition from external laboratories perceived to have more advanced equipment and staff.<br /><br />Resistance to reflex testing was observed due to a limited understanding of clinical indications for biomarker testing and limited clinical information available at the time of diagnosis. The lack of standardization in biomarker testing processes, despite the availability of electronic health record solutions, was also noted as a contributing factor to delays and clinician burden.<br /><br />The study suggests potential solutions to improve the efficiency of biomarker testing processes. These include reflex testing initiated by pathology upon diagnosis, standard operating procedures and streamlined communication for ordering tests and receiving results, and educating and supporting pathologists in their knowledge of biomarkers and reflex testing. Streamlining the ordering processes could benefit health systems overall.<br /><br />In conclusion, this study sheds light on the perspectives and challenges surrounding biomarker testing in an academic medical center. By identifying barriers and suggesting potential solutions, the researchers aim to improve workflow efficiency and increase the utilization of biomarker testing in NSCLC treatment.

Keywords

biomarker testing

non-small cell lung cancer

NSCLC

clinicians

current practices

challenges

health system

barriers

ordering tests

receiving results